+36.1%
HUT vs MRNA
+697.5%
-661.4%
-65.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -17.7% | -2.2% | -15.5% | -17.5% |
| 7D | -20.2% | -12.7% | -7.5% | -19.6% |
| 30D | -35.8% | -20.7% | -15.1% | -35.1% |
| 3M | -48.2% | +46.3% | -94.4% | -49.2% |
| 6M | -52.4% | +305.2% | -357.6% | -64.3% |
| YTD | 0.0% | +561.2% | -561.2% | -42.5% |
| 1Y | +36.1% | +772.1% | -736.0% | -41.5% |
| All | +36.1% | +697.5% | -661.4% | -41.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling